Why do I feel less pain after taking Etrasimod-Velsipity?
Etrasimod is a selective S1P receptor modulator developed by Pfizer, with the trade name Velsipity. It was originally used to treat inflammatory bowel diseases such as moderate to severe ulcerative colitis (UC). Many patients report "rapid pain relief" after starting the medication. This is not a direct effect of the analgesics, but the comprehensive effect of itrimod's precise intervention on the immune-inflammatory response.
Itramod selectively regulatesS1P1 receptor, causing overactive lymphocytes to temporarily stay in lymph nodes, thereby reducing the number of them entering the intestinal mucosa. It is this "immune traffic control" mechanism that reduces inflammatory factors and immune attacks, alleviates intestinal wall edema and tissue damage, and then reduces the subjective pain experienced by patients. In other words, the rapid onset of action of the drug is not to suppress neural pain sensation, but to control the inflammatory response from the source.
Research shows that the onset of effect of istrimod is usually within days to weeks, but some patients experience relief of abdominal pain, burning or flatulence in the early stages of medication. This is closely related to the individual's immune activity, intestinal mucosal repair speed and metabolic rate. In addition, it can indirectly regulate the nerve-immune pathway at the molecular level, reducing the release of inflammatory mediators (such as IL-17, TNF-α), thereby reducing the sensitivity of nerve endings, manifesting as "pain relief."
Unlike traditional immunosuppressive drugs, itridimod works accurately, reversibly and is well tolerated. It does not belong to anesthesia or analgesic drugs, so"It doesn't hurt when you eat it" is an indirect effect brought about by immune regulation, reflecting an early signal of inflammation control. Some patients may have enhanced subjective perceptions of efficacy due to psychological comfort or recovery of intestinal function.
Reference materials:https://www.drugs.com/mtm/etrasimod.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)